Medivation's prostate cancer drug cleared for Ph III trial
US drugmaker Medivation has received written permission from the Food and Drug Administration to begin a pivotal Phase III trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy.
The placebo-controlled, double-blind, multinational study will enroll approximately 1,200 patients who will be randomized to receive either MDV3100 or placebo. The primary endpoint of the trial will be overall survival. The firm says it will work to begin the Phase III clinical development of MDV3100 "as quickly as possible this year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze